These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 23548265

  • 1. Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
    Kryeziu K, Jungwirth U, Hoda MA, Ferk F, Knasmüller S, Karnthaler-Benbakka C, Kowol CR, Berger W, Heffeter P.
    Mol Cancer Ther; 2013 Jun; 12(6):1073-84. PubMed ID: 23548265
    [Abstract] [Full Text] [Related]

  • 2. TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis.
    Liu ZM, Tseng HY, Cheng YL, Yeh BW, Wu WJ, Huang HS.
    Toxicol Appl Pharmacol; 2015 May 15; 285(1):41-50. PubMed ID: 25791921
    [Abstract] [Full Text] [Related]

  • 3. Targeting of EGFR increase anti-cancer effects of arsenic trioxide: Promising treatment for glioblastoma multiform.
    Mesbahi Y, Zekri A, Ahmadian S, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH.
    Eur J Pharmacol; 2018 Feb 05; 820():274-285. PubMed ID: 29274334
    [Abstract] [Full Text] [Related]

  • 4. Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.
    Boyko-Fabian M, Niehr F, Distel L, Budach V, Tinhofer I.
    PLoS One; 2014 Feb 05; 9(6):e98867. PubMed ID: 24927258
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
    Liu ZM, Tseng JT, Hong DY, Huang HS.
    Biochem J; 2011 Sep 01; 438(2):349-58. PubMed ID: 21649584
    [Abstract] [Full Text] [Related]

  • 7. Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
    Lam SK, Li YY, Zheng CY, Ho JC.
    Int J Oncol; 2015 Jan 01; 46(1):113-22. PubMed ID: 25335113
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer.
    Guilbert C, Annis MG, Dong Z, Siegel PM, Miller WH, Mann KK.
    PLoS One; 2013 Jan 01; 8(12):e85995. PubMed ID: 24392034
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells.
    Li L, Wang H, Yang ES, Arteaga CL, Xia F.
    Cancer Res; 2008 Nov 15; 68(22):9141-6. PubMed ID: 19010885
    [Abstract] [Full Text] [Related]

  • 15. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
    Zheng CY, Lam SK, Li YY, Fong BM, Mak JC, Ho JC.
    Lung Cancer; 2013 Nov 15; 82(2):222-30. PubMed ID: 24041618
    [Abstract] [Full Text] [Related]

  • 16. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY, Chao TT, Chang FY, Chen YL, Tsai YT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF.
    Lung Cancer; 2014 Aug 15; 85(2):152-60. PubMed ID: 24954871
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.
    Lang M, Wang X, Wang H, Dong J, Lan C, Hao J, Huang C, Li X, Yu M, Yang Y, Yang S, Ren H.
    Cancer Lett; 2016 Aug 10; 378(2):87-96. PubMed ID: 27212442
    [Abstract] [Full Text] [Related]

  • 19. SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells.
    Kodigepalli KM, Dutta PS, Bauckman KA, Nanjundan M.
    FEBS Lett; 2013 Jan 04; 587(1):5-16. PubMed ID: 23178716
    [Abstract] [Full Text] [Related]

  • 20. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.
    Mol Cancer Ther; 2012 Oct 04; 11(10):2149-57. PubMed ID: 22844075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.